P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study
| العنوان: | P604 Can we reduce intravenous monoclonal antibody observation times without compromising patient safety? A single centre retrospective observational study |
|---|---|
| المؤلفون: | G Scutt, E Hills, A Packham, Fiona Rees, C Blake, A St Clair-Jones |
| المصدر: | Journal of Crohn's and Colitis. 14:S504-S505 |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | medicine.medical_specialty, Palliative care, medicine.drug_class, business.industry, Medical record, Gastroenterology, Retrospective cohort study, General Medicine, Monoclonal antibody, Infliximab, Surgery, Vedolizumab, Patient safety, medicine, Adverse effect, business, medicine.drug |
| الوصف: | Background Monoclonal antibodies (MAbs) are integral to inflammatory bowel disease (IBD) management. The administration of intravenous (IV) MAbs, infliximab and vedolizumab, for Brighton and Sussex University Hospital patients is via an outpatient clinic. Licensing specifies lengthy observation times; infliximab for induction (infusion 1 to 3) and maintenance (infusion 4 onwards) requires 1 to 2 h observation. Vedolizumab for induction (infusion 1 to 2) requires 2 h observation and maintenance (infusion 3 onwards) 1-h observation. This can affect waiting times; 33% UK patients waited longer than two weeks for infliximab. A reduction in observation times could improve capacity but needs to be done without compromising patient safety. Methods A single centre observational study was conducted. Retrospective data were collected on all current patients receiving infliximab or vedolizumab at BSUH. Data were collected over 12 weeks (April to July 2019); patients seen twice in this period were included once. The presence of reaction from current and previous infusions was determined by patient questioning and patient records review. Reaction occurrence, nature and management were recorded. There is not a grading system for IBD infusion-related reactions. To standardise we used the cancer Common Terminology Criteria for Adverse Events; grade 3 and above is designated severe (grade 5 being death). Results For infliximab 130 patients were reviewed with 2607 infusions administered in total. For vedolizumab 69 patients were reviewed with 557 infusions administered in total. Due to the small sample size significance could not be reached. The survival plot indicates high levels of ‘no reactions’ observed in the first 4 infusions of infliximab 97.7% (+1.6%, -4.7%), and first 3 infusions of vedolizumab 96.9% (+2.3%, −8.8%). Considering capacity over 12 weeks, for infliximab a minimum of 121 could be recouped and 64 h for vedolizumab. Extrapolated this could equate to 740 h per year. Conclusion All reactions occurred within three infusions, were non-severe and managed within the infusion clinic. By removing the observation period from infusion 4 onwards, infusion clinic capacity could be increased but further data from multiple centres are required to prove significance. |
| تدمد: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjz203.732 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::d7cbf9561464415259cf12d697cfe1b4 https://doi.org/10.1093/ecco-jcc/jjz203.732 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........d7cbf9561464415259cf12d697cfe1b4 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18764479 18739946 |
|---|---|
| DOI: | 10.1093/ecco-jcc/jjz203.732 |